Background: Dihydroartemisinin-piperaquine (DHA-PQ) is highly efficacious as intermittent preventive therapy for malaria during pregnancy (IPTp). Determining associations between piperaquine (PQ) exposure, malaria risk, and adverse birth outcomes informs optimal dosing strategies. Methods: Human immunodeficiency virus-uninfected pregnant women (n = 300) were enrolled in a placebo-controlled trial of IPTp at 12-20 weeks' gestation and randomized to sulfadoxine-pyrimethamine every 8 weeks, DHA-PQ every 8 weeks, or DHA-PQ every 4 weeks during pregnancy. Pharmacokinetic sampling for PQ was performed every 4 weeks, and an intensive pharmacokinetic substudy was performed in 30 women at 28 weeks' gestation. Concentration-effect relationships were assessed between exposure to PQ; the prevalence of Plasmodium falciparum infection during pregnancy; outcomes at delivery including placental malaria, low birth weight, and preterm birth; and risks for toxicity. Simulations of new dosing scenarios were performed. Results: Model-defined PQ target venous plasma concentrations of 13.9 ng/mL provided 99% protection from P. falciparum infection during pregnancy. Each 10-day increase in time above target PQ concentrations was associated with reduced odds of placental parasitemia, preterm birth, and low birth weight, though increases in PQ concentrations were associated with QT interval prolongation. Modeling suggests that daily or weekly administration of lower dosages of PQ, compared to standard dosing, will maintain PQ trough levels above target concentrations with reduced PQ peak levels, potentially limiting toxicity. Conclusions: The protective efficacy of IPTp with DHA-PQ was strongly associated with higher drug exposure. Studies of the efficacy and safety of alternative DHA-PQ IPTp dosing strategies are warranted. Clinical Trials Registration: NCT02163447.
RCT Entities:
Background: Dihydroartemisinin-piperaquine (DHA-PQ) is highly efficacious as intermittent preventive therapy for malaria during pregnancy (IPTp). Determining associations between piperaquine (PQ) exposure, malaria risk, and adverse birth outcomes informs optimal dosing strategies. Methods:Human immunodeficiency virus-uninfected pregnant women (n = 300) were enrolled in a placebo-controlled trial of IPTp at 12-20 weeks' gestation and randomized to sulfadoxine-pyrimethamine every 8 weeks, DHA-PQ every 8 weeks, or DHA-PQ every 4 weeks during pregnancy. Pharmacokinetic sampling for PQ was performed every 4 weeks, and an intensive pharmacokinetic substudy was performed in 30 women at 28 weeks' gestation. Concentration-effect relationships were assessed between exposure to PQ; the prevalence of Plasmodium falciparum infection during pregnancy; outcomes at delivery including placental malaria, low birth weight, and preterm birth; and risks for toxicity. Simulations of new dosing scenarios were performed. Results: Model-defined PQ target venous plasma concentrations of 13.9 ng/mL provided 99% protection from P. falciparum infection during pregnancy. Each 10-day increase in time above target PQ concentrations was associated with reduced odds of placental parasitemia, preterm birth, and low birth weight, though increases in PQ concentrations were associated with QT interval prolongation. Modeling suggests that daily or weekly administration of lower dosages of PQ, compared to standard dosing, will maintain PQ trough levels above target concentrations with reduced PQ peak levels, potentially limiting toxicity. Conclusions: The protective efficacy of IPTp with DHA-PQ was strongly associated with higher drug exposure. Studies of the efficacy and safety of alternative DHA-PQ IPTp dosing strategies are warranted. Clinical Trials Registration: NCT02163447.
Authors: Joel Tarning; Marcus J Rijken; Rose McGready; Aung Pyae Phyo; Warunee Hanpithakpong; Nicholas P J Day; Nicholas J White; François Nosten; Niklas Lindegardh Journal: Antimicrob Agents Chemother Date: 2012-01-17 Impact factor: 5.191
Authors: Moses R Kamya; Emmanuel Arinaitwe; Humphrey Wanzira; Agaba Katureebe; Chris Barusya; Simon P Kigozi; Maxwell Kilama; Andrew J Tatem; Philip J Rosenthal; Chris Drakeley; Steve W Lindsay; Sarah G Staedke; David L Smith; Bryan Greenhouse; Grant Dorsey Journal: Am J Trop Med Hyg Date: 2015-03-16 Impact factor: 2.345
Authors: Stephanie Dellicour; Andrew J Tatem; Carlos A Guerra; Robert W Snow; Feiko O ter Kuile Journal: PLoS Med Date: 2010-01-26 Impact factor: 11.069
Authors: J Tarning; E A Ashley; N Lindegardh; K Stepniewska; L Phaiphun; N P J Day; R McGready; M Ashton; F Nosten; N J White Journal: Antimicrob Agents Chemother Date: 2008-01-07 Impact factor: 5.191
Authors: Jesmin Permala; Joel Tarning; François Nosten; Nicholas J White; Mats O Karlsson; Martin Bergstrand Journal: Antimicrob Agents Chemother Date: 2017-04-24 Impact factor: 5.191
Authors: Patrick G T Walker; Feiko O ter Kuile; Tini Garske; Clara Menendez; Azra C Ghani Journal: Lancet Glob Health Date: 2014-07-23 Impact factor: 26.763
Authors: Heidi Hopkins; Iveth J González; Spencer D Polley; Patrick Angutoko; John Ategeka; Caroline Asiimwe; Bosco Agaba; Daniel J Kyabayinze; Colin J Sutherland; Mark D Perkins; David Bell Journal: J Infect Dis Date: 2013-04-30 Impact factor: 5.226
Authors: Erika Wallender; Nan Zhang; Melissa Conrad; Abel Kakuru; Mary Muhindo; Patrick Tumwebaze; Richard Kajubi; Daniel Mota; Jennifer Legac; Prasanna Jagannathan; Diane Havlir; Moses Kamya; Grant Dorsey; Francesca Aweeka; Philip J Rosenthal; Rada M Savic Journal: Antimicrob Agents Chemother Date: 2019-01-29 Impact factor: 5.191
Authors: Brioni R Moore; John M Benjamin; Roselyn Tobe; Maria Ome-Kaius; Gumul Yadi; Bernadine Kasian; Charles Kong; Leanne J Robinson; Moses Laman; Ivo Mueller; Stephen Rogerson; Timothy M E Davis Journal: Antimicrob Agents Chemother Date: 2019-09-23 Impact factor: 5.191
Authors: Emma Hughes; Erika Wallender; Richard Kajubi; Prasanna Jagannathan; Teddy Ochieng; Abel Kakuru; Moses R Kamya; Tamara D Clark; Philip J Rosenthal; Grant Dorsey; Francesca Aweeka; Radojka M Savic Journal: Clin Infect Dis Date: 2022-08-31 Impact factor: 20.999
Authors: Palang Chotsiri; Julie R Gutman; Rukhsana Ahmed; Jeanne Rini Poespoprodjo; Din Syafruddin; Carole Khairallah; Puji B S Asih; Anne L'lanziva; Kephas Otieno; Simon Kariuki; Peter Ouma; Vincent Were; Abraham Katana; Ric N Price; Meghna Desai; Feiko O Ter Kuile; Joel Tarning Journal: Antimicrob Agents Chemother Date: 2021-02-17 Impact factor: 5.191